CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Vaccinogen, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Vaccinogen, Inc.
949 Fell Street
Phone: (410) 387-4000p:410 387-4000 Baltimore, MD  21231-3505  United States Fax: (301) 631-2970f:301 631-2970
This company is no longer actively traded on any major stock exchange.
Business Summary
Vaccinogen, Inc. is a biotechnology company. The Company is the developer of OncoVAX. OncoVAX is an active specific immunotherapy (ASI) that uses the patient's own cancer cells to create a vaccine that in turn is used to block the return of cancer following surgery. OncoVAX is a patient specific immunotherapy for stage II colon cancer and its technology may have application in other tumor types, such as melanoma and renal cell carcinoma. The OncoVAX patient-specific vaccine consists of sterile, metabolically active, irradiated and non-tumorigenic autologous cancer cells, with or without fresh frozen Bacillus Calmette-Guerin (BCG) bacteria as an adjuvant. The Company has completed a Phase IIIa study of OncoVAX.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/201512/31/2014YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research
2833 Medicinal chemicals and botanical products

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, President, Chief Executive Officer Andrew L.Tussing 50 5/5/2015 8/22/2014
Chairman Emeritus Michael G.Hanna 79 8/22/2014 8/22/2014
Vice Chairman of the Board Anders Ture G.Halldin 56 8/22/2014 8/22/2014
3 additional Officers and Directors records available in full report.

Business Names
Business Name
Vaccinogen (US) R&D, Inc.
Vaccinogen B.V.
Vaccinogen Bermuda, Ltd.
Vaccinogen International Partners, LP
VGEN

General Information
Number of Employees: 24 (As of 4/10/2015)
Outstanding Shares: 37,321,078 (As of 11/6/2015)
Stock Exchange: OTC
Federal Tax Id: 141997223
Fax Number: (301) 631-2970
Email Address: info@vaccinogeninc.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023